Open Journal Systems

Cover Image

Challenges in Prostate Biopsy

Mark J Ferretti, Jonathan Bloom


Prostate cancer is a leading cause of death among US males.  Great advances have been made in the diagnosis and treatment of prostate cancer.  Particularly Prostate Specific Antigen (PSA) screening and the transrectal ultrasound-guided prostate biopsy (TRUS-BX) have been instrumental in achieving success in this field.  This mini-review analyzes challenges in regards to the prostate biopsy and diagnosis of prostate cancer.


Imaging Guided Biopsy, Prostate Specific Antigen, Prostatic Neoplasms, Prostate

Full Text:



Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT, Raman JD: Complications following prostate needle biopsy requiring hospital admission or emergency department visits–experience from 1000 consecutive cases. BJU international 2012, 110:369-374.


Wolf JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ: Best practice policy statement on urologic surgery antimicrobial prophylaxis. The Journal of urology 2008, 179:1379-1390.


Vickers AJ: Four Flawed Arguments Against Prostate-specific Antigen Screening (and 1 Good One). Urology 2015, 85:491-494.


Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, Karnofski K, Gulati R, Penson DF, Feuer E: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes & Control 2008, 19:175-181.

PMid:18027095 PMCid:PMC3064270

Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, Colon I: The incidence of fluoroquinolone resistant infections after prostate biopsy—are fluoroquinolones still effective prophylaxis? The Journal of urology 2008, 179:952-955.


Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM: Complications after prostate biopsy: data from SEER-Medicare. The Journal of urology 2011, 186:1830-1834.


Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. The Journal of urology 2010, 183:963-969.


Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM: Quality-of-life effects of prostate-specific antigen screening. New England Journal of Medicine 2012, 367:595-605.


Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P: Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European urology 2013, 63:88-96.


Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM: Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine 2012, 367:203-213.

PMid:22808955 PMCid:PMC3429335

Vickers A, Bennette C, Steineck G, Adami H-O, Johansson J-E, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L: Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. European urology 2012, 62:204-209.

PMid:22541389 PMCid:PMC3389180

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Bmj 2010, 341:c4521.

PMid:20843935 PMCid:PMC2939950

Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS: Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011, 77:1035-1041.


Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, Agarwal H, Shah V, Bernardo M, Pang Y: Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013, 268:144-152.

PMid:23468576 PMCid:PMC3689450

Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ: Prostate cancer: value of multiparametric mr imaging at 3 t for detection—histopathologifc correlation 1. Radiology 2010, 255:89-99.

PMid:20308447 PMCid:PMC2843833

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ: ESUR prostate MR guidelines 2012. European radiology 2012, 22:746-757.

PMid:22322308 PMCid:PMC3297750

Vargas HA, Akin O, Franiel T, Goldman DA, Udo K, Touijer KA, Reuter VE, Hricak H: Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology 2012, 262:894-902.

PMid:22357889 PMCid:PMC3285222

Tan CH, Wei W, Johnson V, Kundra V: Diffusion Weighted Magnetic Resonance Imaging in Prostate Cancer: Meta-analysis. AJR. American journal of roentgenology 2012, 199:822.

PMid:22997374 PMCid:PMC3888871

Panebianco V, Sciarra A, Marcantonio A, Forte V, Biondi T, Laghi A, Catalano C: Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2012, 56:331.

Jie C, Rongbo L, Ping T: The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis. European radiology 2014, 24:1929-1941.

PMid:24865693 PMCid:PMC4082652

Puech P, Potiron E, Lemaitre L, Leroy X, Haber G-P, Crouzet S, Kamoi K, Villers A: Dynamic contrast-enhanced–magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009, 74:1094-1099.


Tan CH, Paul Hobbs B, Wei W, Kundra V: Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. American Journal of Roentgenology 2015, 204:W439-W448.


Garcia-Reyes K, Passoni NM, Palmeri ML, Kauffman CR, Choudhury KR, Polascik TJ, Gupta RT: Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdominal imaging 2015, 40:134-142.

PMid:25034558 PMCid:PMC4419362

Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM: Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. European urology 2015, 67:1112-1121.


Sonn GA, Margolis DJ, Marks LS: Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2014:903-911.

Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S: A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. The Journal of urology 2011, 186:2214-2220.


Cool DW, Zhang X, Romagnoli C, Izawa JI, Romano WM, Fenster A: Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. American Journal of Roentgenology 2015, 204:83-91.


Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C: Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2015:17. e11-17. e17.

Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS: Value of targeted prostate biopsy using magnetic resonance–ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. European urology 2014, 65:809-815.

PMid:23523537 PMCid:PMC3858524

Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, Beecher K, Vira MA, Kavoussi LR, Siegel DN: Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. The Journal of urology 2014, 191:1749-1754.


Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, Seo SI, Jeong BC, Choi HY: Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound–guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. American Journal of Roentgenology 2011, 197:W876-W881.


Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH: Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naive men with suspected prostate cancer based on elevated prostate-specific antigen values: results from a randomized prospective blinded controlled trial. European urology 2015.


Diaz AW, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C: Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2015:202. e201-202. e207.

Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A, Turkbey B, Choyke PL, Wood BJ, Simon RM: Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. The Journal of urology 2015, 193:1943-1949.


McClure TD, Margolis DJ, Reiter RE, Sayre JW, Thomas MA, Nagarajan R, Gulati M, Raman SS: Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012, 262:874-883.


Park BH, Jeon HG, Jeong BC, Seo SI, Lee HM, Choi HY, Jeon SS: Influence of magnetic resonance imaging in the decision to preserve or resect neurovascular bundles at robotic assisted laparoscopic radical prostatectomy. The Journal of urology 2014, 192:82-88.


Wink M, Frauscher F, Cosgrove D, Chapelon J-Y, Palwein L, Mitterberger M, Harvey C, Rouvière O, De La Rosette J, Wijkstra H: Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. European urology 2008, 54:982-993.


Postema AW, Frinking PJ, Smeenge M, De Reijke TM, De la Rosette JJ, Tranquart F, Wijkstra H: Dynamic contrastâ€enhanced ultrasound parametric imaging for the detection of prostate cancer. BJU international 2015.


Jeon SS, Woo S-H, Hyun J-H, Choi HY, Chai SE: Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. Urology 2003, 62:461-466.

Sabler IM, Lazarovitch T, Haifler M, Lang E, Shapira G, Zelig S, Lindner A, Zisman A: Sterility of Reusable Transrectal Ultrasound Transducer Assemblies for Prostate Biopsy Reprocessed According to Food and Drug Administration Guidelines—Bacteriologic Outcomes in a Clinical Setup. Urology 2011, 77:17-19.


Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH: Bacterial sepsis after prostate biopsy—a new perspective. Urology 2009, 74:1200-1205.


Lorber G, Benenson S, Rosenberg S, Gofrit ON, Pode D: A single dose of 240 mg gentamicin during transrectal prostate biopsy significantly reduces septic complications. Urology 2013, 82:998-1003.


Luong B, Danforth T, Visnjevac O, Suraf M, Duff M, Chevli KK: Reduction in Hospital Admissions With the Addition of Prophylactic Intramuscular Ceftriaxone Before Transrectal Ultrasonography–guided Prostate Biopsies. Urology 2015, 85:511-516.


Liss MA, Peeples AN, Peterson EM: Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. Journal of clinical microbiology 2011, 49:1116-1118.

PMid:21177893 PMCid:PMC3067719

Duplessis CA, Bavaro M, Simons MP, Marguet C, Santomauro M, Auge B, Collard DA, Fierer J, Lesperance J: Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012, 79:556-563.


Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J: Fluoroquinoloneâ€resistant E. coli in intestinal flora of patients undergoing transrectal ultrasoundâ€guided prostate biopsy—should we reassess our practices for antibiotic prophylaxis? Clinical Microbiology and Infection 2012, 18:575-581.


Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D, Machan L, Black P: Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU international 2013, 111:946-953.


Liss MA, Kim W, Moskowitz D, Szabo RJ: Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. The Journal of urology 2015, 194:397-402.


Jones JS, Oder M, Zippe CD: Saturation prostate biopsy with periprostatic block can be performed in office. The Journal of urology 2002, 168:2108-2110.


Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A: The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. The Journal of urology 2001, 166:2242-2246.


Carey JM, KORMAN HJ: Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? The Journal of urology 2001, 166:82-85.



  • There are currently no refbacks.